Abstract:BackgroundImmuno-oncotherapy has emerged as a promising means to target cancer. In particular, therapeutic manipulation of tumor-associated macrophages holds promise due to their various and sometimes opposing roles in tumor progression. It is established that M1-type macrophages suppress tumor progression while M2-types support it. Recently, Tie2-expressing macrophages (TEM) have been identified as a distinct sub-population influencing tumor angiogenesis and vascular remodeling as well as monocyte differentiation.MethodsThis study develops a modeling framework to evaluate macrophage interactions with the tumor microenvironment, enabling assessment of how these interactions may affect tumor progression. M1, M2, and Tie2 expressing variants are integrated into a model of tumor growth representing a metastatic lesion in a highly vascularized organ, such as the liver. Behaviors simulated include M1 release of nitric oxide (NO), M2 release of growth-promoting factors, and TEM facilitation of angiogenesis via Angiopoietin-2 and promotion of monocyte differentiation into M2 via IL-10.ResultsThe results show that M2 presence leads to larger tumor growth regardless of TEM effects, implying that immunotherapeutic strategies that lead to TEM ablation may fail to restrain growth when the M2 represents a sizeable population. As TEM pro-tumor effects are less pronounced and on a longer time scale than M1-driven tumor inhibition, a more nuanced approach to influence monocyte differentiation taking into account the tumor state (e.g., under chemotherapy) may be desirable.ConclusionsThe results highlight the dynamic interaction of macrophages within a growing tumor, and, further, establish the initial feasibility of a mathematical framework that could longer term help to optimize cancer immunotherapy.

Mathematical model of tumor immune microenvironment with application to the combined therapy targeting the PD-1/PD-L1 pathway and IL-10 cytokine antibody

A mathematical model of tumor-immune interactions incorporated with danger model

Mathematical Modeling of Tumor Immune Interactions: The Role of Anti-FGFR and Anti-PD-1 in the Combination Therapy

Data-driven mathematical modeling and quantitative analysis of cell dynamics in the tumor microenvironment

Mathematical modeling of cancer treatment with radiation and PD-L1 inhibitor

Mathematical Modeling and Analysis of Tumor Growth in response to a Mixed Chemotherapy and Immune Checkpoint Inhibition Therapy

Mathematical Modeling of the Synergetic Effect between Radiotherapy and Immunotherapy

Mathematical Modeling of Interleukin-35 Promoting Tumor Growth and Angiogenesis.

Investigating the synergistic effects of immunotherapy and normalization treatment in modulating tumor microenvironment and enhancing treatment efficacy

Mathematical modeling of combined therapies for treating tumor drug resistance

A biomathematical model of tumor response to radioimmunotherapy with $α$PDL1 and $α$CTLA4

Advances in models predicting efficacy of immune checkpoint inhibitors

Mathematical modeling and dynamic analysis of anti-tumor immune response

Prediction Of Treatment Efficacy For Prostate Cancer Using A Mathematical Model

Modeling tumour heterogeneity of PD-L1 expression in tumour progression and adaptive therapy

Treatment of Melanoma with Dendritic Cell Vaccines and Immune Checkpoint Inhibitors: A Mathematical Modeling Study

Computational Modeling to Determine the Effect of Phenotypic Heterogeneity in Tumors on the Collective Tumor–Immune Interactions

Mathematical Modeling of Interleukin-27 Induction of Anti-Tumor T Cells Response.

Modelling Pulsed Immunotherapy of Tumour-Immune Interaction

Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment

Mathematical modeling of cancer immunotherapy for personalized clinical translation